Risk Factors for Mortality in Stable Kidney Transplant Patients Infected by SARS-CoV-2 in the South of Spain

dc.contributor.authorLopez, Veronica
dc.contributor.authorVazquez-Sanchez, Teresa
dc.contributor.authorCasas, Cristina
dc.contributor.authorSchuldt, Ruben
dc.contributor.authorAlonso-Titos, Juana
dc.contributor.authorRuiz-Esteban, Pedro
dc.contributor.authorCabello, Mercedes
dc.contributor.authorHernandez, Domingo
dc.contributor.authoraffiliation[Lopez, Veronica] Hosp Reg Univ Malaga, Nephrol Dept, Ave Carlos Haya, Malaga 29010, SpainUniv Malaga, IBIMA Malaga Inst Biomed Res, REDinREN RD16 0009 0006, Malaga, Spain
dc.contributor.funderInstituto de Salud Carlos III, Madrid, Spain
dc.contributor.funderInstituto de Salud Carlos III, Madrid, Spain (REDinREN Network)
dc.contributor.funderFONDOS FEDER
dc.date.accessioned2025-01-07T12:19:05Z
dc.date.available2025-01-07T12:19:05Z
dc.date.issued2021-11-23
dc.description.abstractBackground. The coronavirus disease 2019 (COVID-19) pandemic has especially affected kidney transplant (KT) recipients, who are more vulnerable than the general population because of their immunosuppressive status and added comorbidities. The purpose of this study was to determine risk factors related to infection and mortality from COVID-19 in KT recipients.Methods. The study included 113 stable KT recipients who had polymerase chain reaction-confirmed COVID-19 infection between March 2020 and February 2021, from a total of 2150 KT recipients. Outcomes related to patient survival were analyzed.Results. The mean (standard deviation) age of the patients was 56 (14) years; 62% (n = 70) were men. The median time between KT and infection was 88 months (interquartile range, 39-155 months); 90% (n = 102) were on tacrolimus therapy and 81% (n = 92) on mycophenolate mofetil. The clinical presentation was pneumonia (n = 57; 51%), fever (n = 61; 54%), cough (n = 62; 55%), dyspnea (n = 43; 38%), lymphopenia (n = 57; 50%), and gastrointestinal symptoms (n = 28; 25%). A total of 21% (n = 24) required intubation and intensive care unit admission, and 27 patients (25%) were asymptomatic. A total of 9% (n = 10) received hydroxychloroquine therapy plus azithromycin, 11% (n = 12) tocilizumab, 3.7% (n = 4) lopinavir/ritonavir, 49% (n = 55) steroids, 0.9% (n = 1) remdesivir, and 9.3% (n = 11) convalescent plasma. Immunosuppression was reduced in all symptomatic patients. Nineteen patients (17%) died. Cox univariate analysis showed that the factors significantly associated with death were patient age, presence of pneumonia or lymphopenia, and elevated C-reactive protein on admission.Conclusions. Mortality in KT recipients with COVID-19 is very high, more than for the general population. Risk factors are patient age, presence of pneumonia or lymphopenia, and a higher C-reactive protein level at the time of diagnosis.
dc.identifier.doi10.1016/j.transproceed.2021.06.029
dc.identifier.essn1873-2623
dc.identifier.issn0041-1345
dc.identifier.pmid34629188
dc.identifier.unpaywallURLhttps://doi.org/10.1016/j.transproceed.2021.06.029
dc.identifier.urihttps://hdl.handle.net/10668/24451
dc.identifier.wosID755390700011
dc.issue.number9
dc.journal.titleTransplantation proceedings
dc.journal.titleabbreviationTransplant. proc.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Regional de Málaga
dc.organizationInstituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)
dc.page.number2685-2687
dc.publisherElsevier science inc
dc.rights.accessRightsopen access
dc.titleRisk Factors for Mortality in Stable Kidney Transplant Patients Infected by SARS-CoV-2 in the South of Spain
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number53
dc.wostypeArticle

Files